Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:

　　Developed by Novartis,Trametinib(brand name:Mekinist)is an oral,selective MEK1/2 inhibitor designed to target the RAS-RAF-MEK-ERK signaling pathway—a pivotal driver of cancer cell proliferation.By blocking MEK kinase activity,it disrupts oncogenic signals,offering life-changing treatment options for:

　　Indications:

　　1.Monotherapy:

　　○Unresectable or metastatic melanoma with BRAF V600E/K mutations,addressing urgent treatment needs.

　　2.Combination Therapy with Dabrafenib:

　　○Adjuvant Treatment for Melanoma:Approved for resected BRAF V600E/K-mutant melanoma with lymph node involvement to prevent recurrence.

　　○Metastatic NSCLC:First-line therapy for BRAF V600E-mutated NSCLC,significantly improving outcomes.

　　○Advanced Cancers:

　　•Anaplastic thyroid carcinoma(ATC)with BRAF V600E.

　　•Systemic treatment for pediatric low-grade glioma(LGG)with BRAF V600E.

　　•Accelerated approval for metastatic solid tumors with BRAF V600E in adults/children≥1 year post-progression,pending confirmatory trials.

　　Mechanism of Action:

　　●Reversible MEK1/2 inhibition that neutralizes constitutive signaling from BRAF mutations.

　　●Synergy with dabrafenib creates a"dual blockade,"enhancing antitumor activity and overcoming single-agent resistance mechanisms,as demonstrated in preclinical models and clinical trials.

　　Safety&Administration:

　　●Common Adverse Events(≥20%with Combo):Fever,fatigue,nausea,rash,hypertension,diarrhea.

　　●Critical Risk Mitigation:

　　a.Hemorrhage:Monitor for severe bleeding events;cautious with antithrombotics.

　　b.Cardiomyopathy:Baseline and periodic LVEF assessments required.

　　c.Ocular Toxicity:Immediate ophthalmic evaluation for vision changes;permanent discontinuation for retinal vein occlusion(RVO).

　　d.Skin Toxicities:Manage grades 2-4 rash;discontinue for Stevens-Johnson syndrome or toxic epidermal necrolysis.

　　e.Pregnancy Risk:Contraindicated in pregnancy due to fetal toxicity;recommend contraception during treatment and 1 week post-dose.

　　Clinical Impact:

　　●In COMBI-AD trial,adjuvant trametinib+dabrafenib achieved 58%3-year relapse-free survival(RFS)in high-risk melanoma.

　　●NSCLC studies report 63%ORR and 9-month median PFS,transforming outcomes for this underserved population.